Icecure Medical (NASDAQ: ICCM) stock is up 80%. ICCM stock has risen on the back of yet another report on how well the treatment works. We say yet another as the stock has long been volatile dependent upon varied reports of how it does work, it doesn’t, it might a bit and so on. The Big Wahoonie, the FDA signing off on it, hasn’t happened as yet, But there are sometimes encouraging signs from other places and then at others knock backs to the idea that it will gain that full authorisation and approval.
As we said about Icecure Medical: “If it’s simply a new surgical technique then that’s something that is picked up surgeon by surgeon. If it’s a new machine or drug then it needs the FDA. But if you can’t do double blind tests then the FDA might be difficult to convince. Which is exactly what has happened: “"We, along with our regulatory consultants, believe the FDA's response to the De Novo Classification request is largely due to the FDA's need for additional scientific literature as a comparator rate of recurrence in patients treated with lumpectomy.” As you can’t do double blinds then the new treatment has to be compared to the survival rates of those treated in some other manner. Which is what the FDA is insisting upon. That’s what caused the halving of the ICCM stock price a couple of weeks back.”
That was back when the ICCM stock price jumped 54% on the back of an encouraging report out of Spain. Which doesn’t solve that FDA problem, but might indicate that the FDA problem is worth solving.
Icecure Medical stock price from Google Finance
The news today driving the price up again: “IceCure Medical (NASDAQ:ICCM) stock soared 85% in pre-market trading Monday in the wake of a presentation of positive data from a study for its cryoablation technology in the treatment of early-stage breast cancer. The Israeli medical device company said the study was conducted at Spain's University Hospital Lucus Augusti with 31 women who opted for IceCure’s ProSense cryoablation technology over surgery to treat their early-stage breast cancer.”
However, note that this is just a re-presentation of that same Spanish information which caused the last leap in the stock price. This is not, in fact, new information, just making that information newly, and more, prominent.
We would therefore suggest that this price movement is likely to fade back. But do not “likely” there, this is not an insistence.
